期刊文献+

瑞替普酶联合低分子肝素治疗ST段抬高型急性心肌梗死的安全性与有效性 被引量:2

Safety and effectiveness of reteplase combined with low-molecular-weight heparin in the treatment of ST segment elevation acute myocardial infarction
下载PDF
导出
摘要 目的探讨瑞替普酶联合低分子肝素治疗ST段抬高型急性心肌梗死的安全性与有效性。方法90例ST段抬高型急性心肌梗死患者,以抽签法分为观察组与对照组,各45例。对照组实施瑞替普酶+普通肝素治疗,观察组实施瑞替普酶+低分子肝素治疗。对比两组血浆脑钠肽(BNP)、并发症发生情况、血管再通及出血事件发生情况。结果观察组血浆BNP为(81.56±24.87)ng/L低于对照组的(189.23±4.32)ng/L,并发症发生率4.44%低于对照组的22.50%,差异有统计学意义(P<0.05)。两组血管再通率比较,差异无统计学意义(P>0.05);观察组出血事件发生率4.44%低于对照组的24.44%,差异有统计学意义(P<0.05)。结论瑞替普酶联合低分子肝素治疗ST段抬高型急性心肌梗死,可改善患者的血浆BNP水平,并降低并发症,保证治疗的安全性,值得临床上广泛借鉴。 Objective To discuss the safety and effectiveness of reteplase combined with low-molecularweight heparin in the treatment of ST segment elevation acute myocardial infarction.Methods A total of 90 patients with ST-segment elevation acute myocardial infarction were divided into observation group and control group by drawing lots,with 45 cases in each group.The control group was treated with reteplase and unfractionated heparin,and the observation group was treated with reteplase and low-molecular-weight heparin.The plasma brain natriuretic peptide(BNP),complications,vascular recanalization and occurrence of bleeding events were compared between the two groups.Results The plasma BNP of the observation group was(81.56±24.87)ng/L,which was lower than(189.23±4.32)ng/L of the control group,and the complication rate 4.44%of the observation group was lower than 22.50%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the vascular recanalization rate between the two groups(P>0.05).The occurrence of bleeding events 4.44%of the observation group was lower than 24.44%of the control group,and the difference was statistically significant(P<0.05).Conclusion Reteplase combined with low-molecular-weight heparin in the treatment of ST segment elevation acute myocardial infarction can improve the plasma BNP level of patients,reduce complications and ensure the safety of treatment,which is worthy of extensive reference in clinical practice.
作者 陶维柱 TAO Wei-zhu(Fuxin Mine General Hospital of Liaoning Health Industry Group,Fuxin 123000,China)
出处 《中国现代药物应用》 2022年第3期132-134,共3页 Chinese Journal of Modern Drug Application
关键词 瑞替普酶 低分子肝素 ST段抬高型 急性心肌梗死 安全性 有效性 Reteplase Low-molecular-weight heparin ST segment elevation Acute myocardial infarction Safety Effectiveness
  • 相关文献

参考文献7

二级参考文献39

共引文献42

同被引文献22

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部